After 27.4 months of follow-up, data from the KEYNOTE-716 study continue to support the benefit of adjuvant pembrolizumab in reducing the risk of recurrence and distant metastasis in patients with stage IIB or IIC melanoma. Georgina V. Long, MD, PhD, FRACP, of the Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospital, presented these results as part 1 of the KEYNOTE-716 trial at the 2022 ASCO Annual Meeting. Study Details 976 patients with complete resection of cutaneous stage IIB or IIC melanoma and negative sentinel lymph node biopsy were randomized 1:1 to receive pembrolizumab 200 mg or placebo every 3 weeks for 17 cycles (approximately 1 year) in Part 1 of the study. Treatment continued until disease recurrence or unacceptable toxicity. Patients who received placebo in Part 1 or who did not experience disease progression within 6 months of completing Part 1 were eligible for additional cycles of pembrolizumab every 3 weeks at recurrence (Part 2). The primary endpoint was recurrence-free survival (RFS) according to the investigator. The second endpoint was distant metastasis-free survival (DMFS).
展开▼
